Data Sheet 1_Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in

1,900 patients from 15 studies were analyzed in this systematic review and meta-analysis. The work evaluates the efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies for relapsed/refractory multiple myeloma. It was authored by Jiashun Li and last updated in May 2026.

Use Cases

• Compare pooled progression-free survival and response rates across different bispecific antibody therapies.
• Assess the safety profile of these therapies based on pooled incidences of adverse events like cytokine release syndrome and neutropenia.
• Evaluate the certainty of evidence for these treatments using GRADE methodology.
• Perform subgroup analyses on patient cohorts from prospective clinical trials and real-world studies.

Strengths

• Analysis includes data from 1,900 patients across 17 independently extractable cohorts.
• Reports specific pooled efficacy outcomes, such as a progression-free survival of 8.76 months and an overall response rate of 65.9%.
• Reports specific pooled safety outcomes, including a 67.5% incidence of cytokine release syndrome and a 42.6% incidence of grade ≥3 neutropenia.
• Methodological quality was assessed using MINORS and evidence certainty using GRADE.

Limitations

• Row count and column-level documentation are unknown, which may limit suitability assessment.
• The authors note the evidence is mainly from single-arm trials and retrospective studies, with low to very low certainty.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of prospective clinical trials and real-world studies, sourced from databases like Cochrane Library, Embase, PubMed, Scopus, and Web of Science.

Time Range

Literature searched from inception to February 5, 2026.

Freshness

Last updated 2026-05-20 05:45:56; freshness should be verified.